EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Tuesday, October 22nd 2019 at 12:00pm UTC CARLSBAD, Calif.–(BUSINESS WIRE)– Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial Officer, will be presenting at the Dawson James Securities 5th Annual …
Plus »Quotient Sciences Appoints Claes Glassell as Non-Executive Chairman of Board of Directors
Tuesday, October 22nd 2019 at 1:00pm UTC NOTTINGHAM, England–(BUSINESS WIRE)– Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non-executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held …
Plus »Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF Mutation
Monday, October 21st 2019 at 10:01pm UTC BETHESDA, Md.–(BUSINESS WIRE)– Today’s FDA approval of TRIKAFTA (elexacaftor/ivacaftor/tezacaftor), the highly effective and highly anticipated triple-combination CFTR modulator, marks the start of a new era in cystic fibrosis. This medicine represents the single greatest therapeutic advancement in the history of CF, offering a …
Plus »Takeda obtient une licence pour le traitement de la maladie cœliaque de première classe de COUR Pharmaceuticals à la suite d’une étude de validation de principe positive de phase 2a
Tuesday, October 22nd 2019 at 6:15pm UTC ? Les données les plus récentes d’une étude de phase 2a présentée lors de la UEG Week 2019, à Barcelone, en Espagne, soulignent le potentiel de la médecine expérimentale pour prévenir l’activation immunitaire induite par le gluten chez les patients atteints de la …
Plus »Systems Oncology Receives Investment from The Pritzker Organization
Tuesday, October 22nd 2019 at 1:00pm UTC SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both …
Plus »Tiaki Therapeutics Presents Data on Identification of a Novel Target for Neuroinflammatory-driven Neurodegenerative Disease Validated by Its Systems Biology Platform
Monday, October 21st 2019 at 4:00pm UTC Proprietary platform recapitulates neuroinflammatory signature from Alzheimer’s Disease patients Data presented at Society for Neuroscience 49th Annual Meeting CAMBRIDGE, Mass.–(BUSINESS WIRE)– Tiaki Therapeutics, a company developing treatments for patients suffering from age-related dementias by targeting the neuroinflammation that drives cognitive decline, announced today …
Plus »SkyKnight Capital Invests in Home Healthcare Leader AeroCare
Monday, October 21st 2019 at 12:00pm UTC SAN FRANCISCO–(BUSINESS WIRE)– SkyKnight Capital (“SkyKnight”), a San Francisco based private equity firm, announced that it has made an investment into AeroCare Holdings, Inc. (“AeroCare” or the “Company”), a leading provider of home healthcare solutions focused on patients with chronic respiratory conditions. AeroCare …
Plus »Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia
Saturday, October 19th 2019 at 11:29pm UTC LONDON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who have one copy of the …
Plus »AVROBIO Appoints Holly May as Chief Commercial Officer
Tuesday, October 22nd 2019 at 11:00am UTC Company developing commercial strategies and operational capabilities to support future product launches as investigational gene therapies advance through clinic Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.–(BUSINESS WIRE)– AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene …
Plus »Vertex to Announce Third-Quarter 2019 Financial Results on October 30
Monday, October 21st 2019 at 8:07pm UTC BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET. To access the call, please …
Plus »
